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 During the 1990s, the search for breast cancer susceptibility genes identified 
several high-risk genes such as BRCA1&2, TP53, and PTEN. The late 1990s and early 
2000s saw identification of the first intermediate risk genes, ATM, CHEK2, and PALB2. 
With time, however, the likelihood of identifying new high-risk genes is diminishing; on 
the other hand, the technology for hypothesis free, genome-wide identification of 
intermediate risk genes is still being developed. During the mid-2000s, the hunt for the 
genetic basis of breast cancer shifted toward genome-wide searches for modest risk 
breast cancer associated single nucleotide polymorphisms (SNPs). Here, we study a 
panel of 16 such SNPs as a polygene. We demonstrated that the polygene model works 
well for this panel, and that when viewed as a polygene, the composite risk for some 
individuals rises to a level comparable to an intermediate risk gene. We also find that 
the polygene model seems to better differentiate case-control status with increasing 
numbers of SNPs; therefore, we expect that the more SNPs that are added to the 
polygene model, the more accurately risk will be differentiated in the composite odds 
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Common Disease/Common Variant vs. Common Disease/Rare Variant 
Historically, there have been two models to explain genetic predisposition in 
breast cancer: the common disease/common variant (CD/CV) model and the common 
disease/rare variant (CD/RV) model (Pritchard & Cox, 2001; Ivengar, 2007; Schork, 
2009). The common disease/common variant model says that a limited set of sequence 
variants that are common in the population underlie the genetic basis of a common 
disease – in this case, breast cancer (Lander, 1996; Chakravarti, 1999; Reich, 2001). 
The second model argues that there are many rare variants in the population that 
underlie the genetic basis of a common disease (Pritchard, 2001). 
 
Single Nucleotide Polymorphisms 
With the increasing availability of human genome data, it has become clear that 
the differences from one human genome to the next often come down to single 
nucleotide base changes, termed as Single Nucleotide Polymorphisms (SNPs) 
(Chakravarti, 2001). Many SNPs have been identified through Genome-Wide Association 
Studies (GWAS) – studies that examine common variants in large numbers of individuals 
in order to determine whether any association exists between a particular variant and a 
specific trait (Manolio, 2010). It is important to note that in such cases, the SNPs which 
are found to be associated with a trait are often merely markers for genomic locations 
and are selected for their ability to adequately tag the genome (Easton and Eeles, 
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2008). That is, even if the SNP itself is noncoding, it could be tagging an underlying 
coding variant.  
As is the case with a number of genetic diseases, many SNPs have been shown 
to be associated with breast cancer (Houlston, 2004). It is also known that SNPs 
associated with breast cancer risk are distributed throughout the genome, rather than 
being clustered in one particular area (Pharoah, 2002; Easton, 2007; Michailidou, 2013). 
The majority of SNPs associated with breast cancer are noncoding and are therefore 
thought to be regulatory (Easton, 2007).   
 
The Polygene Model 
Until early 2013, there were approximately eighteen well-established breast 
cancer risk SNPs (Wacholder, 2010). In March of 2013, a paper was published which 
established 41 new breast cancer susceptibility SNPs based on multiple Genome-Wide 
Association Studies (GWAS) (Michailidou, 2013). This study by the Collaborative 
Oncological Gene-environment Study (COGS), using a custom Illumina iSelect assay 
termed iCOGS, brought the total number of recognized breast cancer risk SNPs to at 
least 60, with possibly as many as 70 (Michailidou, 2013). Using the data from nine 
previous GWAS using individuals of primarily European descent, Michailidou et al. 
identified a panel of potential SNPs that could be shown to have an association with 
breast cancer. The authors then compiled samples from 52 previous studies that had 
participated in the Breast Cancer Association Consortium (BCAC) and designed a custom 
Illumina assay (iCOGS) with which to interrogate the potential new SNPs. When the 
genotyping of the samples was complete, the authors had identified over 40 new 
associations between SNPs and risk of breast cancer.  
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In terms of risk, the general female population is considered to have 
approximately a 10% lifetime risk of developing breast cancer (Howlader, 2009).  
Hence, a 10% lifetime risk roughly corresponds to an odds ratio of 1.0 on a logarithmic 
scale.  A woman is considered to have a medically actionable level of genetic risk when 
her lifetime risk reaches approximately 20-25%, which roughly corresponds to an odds 
ratio of 2.0-2.5 (Harris, 2007; Ellsworth, 2010). Common breast cancer risk SNPs 
typically have odds ratios on the order of 1.01 to 1.3. Hence, the risk conferred by 
individual risk SNPs has been considered to be medically negligible (Pharoah, 2002; 
Easton, 2007; Michailidou, 2013).  
The polygene model argues that while the increased level of risk is not additive 
across SNPs, it also cannot be discounted (Pharoah, 2002). The individual risk conferred 
by each SNP can be combined multiplicatively in order to determine a composite risk 
level conveyed by the unique combination of SNPs in each woman’s genome. With many 
common, modest-risk alleles, the composite risk may climb to a medically actionable 
level. Additionally, with the very recent addition of a large number of SNPs newly 
identified as being associated with breast cancer by the COGS group, the potential for 
the discovery of polygenic effects of breast cancer risk SNPs has only increased.  
 
Study Question and Hypotheses 
The parent study for this project asked, "What is the relative contribution of 
common (usually modest-risk) sequence variants vs. rare (potentially higher-risk) 
sequence variants to the genetic population attributable fraction of breast cancer?" From 
that question arose our hypotheses. The null hypothesis for this project was that our 
empirical measure of odds ratio associated with the polygene would show no risk 
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associated with the polygene. Conversely, our alternate hypothesis was that the 
empirically measured risk associated with the polygene would be similar to a naïve 
product of all of a subject’s risk SNP genotypes. In the event the null hypothesis is 
rejected, we wanted to estimate the fraction of the population, and the fraction of 









MATERIALS AND METHODS 
Ethics Statement 
The polygene genotyping studies and analysis described here were approved by 
the institutional review board (IRB) of the University of Utah, the International Agency 
for Research on Cancer IRB, and the local IRBs of the Breast Cancer Family Registry 
(Breast CFR) centers from which we received samples. All participants gave written, 
informed consent.  
 
Subjects  
Breast CFRs at three centers (Cancer Care Ontario, the Cancer Prevention 
Institute of California (formerly the Northern California Cancer Center) and the 
University of Melbourne (LeCalvez, 2011)) gathered women by population-based 
sampling methods, from which patients for our study were selected. Patients for these 
Breast CFRs were recruited between 1995 and 2005.  
Patients designated as cases (N=1259) were selected based on diagnosis at or 
before the age of 45 years, self-reported race or ethnicity, and grandparents’ country of 
origin which correlated with Caucasian, East Asian, Hispanic/Latino, or African American 
racial or ethnic heritage. 
Control patients (N=1063) were frequency matched to case patients within each 
study center on racial or ethnic group, with age at selection for study not more than +/- 
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10 years difference of the age range at diagnosis of patients from the same center. A 
shortage of available controls in some age or ethnic groups caused the frequency 
matching to not be one-to-one in all subgroups.  
 
SNP Genotyping 
Genotyping began with whole-genome amplified (WGA) DNA. A nested 
polymerase chain reaction (PCR) with a multiplexed primary PCR was used. This was 
followed by high-resolution melting (HRM) curve analysis to identify major and minor 
alleles. Our panel of sixteen SNPs included variants in FGFR2, XRCC2, and the 8q24 
genomic region, as shown in Table 1.   
Our HRM analysis consisted of two assays, either unlabeled probe or small 
amplicon-based genotyping. Unlabeled probe was used whenever practical, and involved 
a probe of approximately 20 bases designed to be complimentary to the SNP of interest. 
Probes were designed to be complimentary to the major allele by convention. In cases 
where small amplicon-based genotyping was necessary, the secondary PCR amplicon 
was designed to be approximately 50 bases in length, so as to be able to visualize a 
single base change. 
Genotyping began at the World Health Organization’s (WHO) International 
Agency for Research on Cancer (IARC) before moving to the University of Utah’s 
Huntsman Cancer Institute. The location where genotyping was done for each SNP is 
noted in Table 1.  
 
Statistical Analysis 
In order to calculate the polygene odds ratio for each subject, the appropriate 
SNP odds ratio as published by COGS was assigned to each genotype (Michailidou, 
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2013). Based on the 16 genotypes for each particular woman, the appropriate odds ratio 
values were then multiplied together to obtain the subject’s crude polygene risk score. 
Furthermore, the average control polygene risk score was calculated. Each subject’s 
crude polygene OR, case or control, was divided by the average control polygene risk 
score, to produce a normalized polygene risk score.  
Using these normalized polygene risk scores (PRS), individual subjects were 
sorted into one of seven groups: PRS <0.5, 0.5 < PRS < 0.63, 0.63 < PRS < 0.8, 0.8 < 
PRS < 1.26, 1.26 < PRS < 1. 59, 1.59 < PRS < 2.0,  PRS >2.0 (Table 2). Using the 
individual normalized polygene PRS in each group, an empirical estimate of the OR for 




Table 1. Table of SNPs genotyped, rs numbers and major/minor allele, research center 
where subjects were genotyped for that SNP, the inheritance model (PA=per allele, 
REC=recessive), Odds Ratio (OR) as published by COGS, allele frequency (q) of the 
minor allele in the BCAC study as published by COGS, our observed OR, and our 











Observed         
q 
FGFR2 rs2981579, G/A IARC PA 1.27 40% 1.15 48% 
TOX3 rs3803662, G/A IARC  PA 1.24 26% 1.4 27% 
XRCC2 rs3218408 HCI Rec 1.33   1.15 25% 
5p12 rs10941679, A/G HCI  PA 1.13 25% 1.02 28% 
MAP3K1 rs889312, A/C IARC  PA 1.12 28% 1.31 27% 
SLC4A7 rs4973768, C/T HCI  PA 1.10 47% 1.09 48% 
8q24 rs13281615, A/G IARC  PA 1.09 41% 1.13 41% 
1p11.2 rs11249433, A/G HCI  PA 1.09 40% 1.13 53% 
ESR1 rs2046210, G/A HCI  PA 1.08 34% 0.97 39% 
ZMIZ1 rs704010, C/T HCI  PA 1.08 39% 1.01 39% 
LSP1 rs3817198, T/C IARC  PA 1.07 31% 1.15 32% 
ANKRD16 rs2380205, C/T HCI  PA 0.98 44% 0.8 41% 
CASP8 rs1045485, G/C IARC  PA 0.97 13% 1.05 12% 
COX11 rs6504950, G/A HCI  PA 0.94 28% 0.72 33% 
2q35 rs13387042, A/G IARC  PA 0.88 49% 0.92 48% 
ZNF365 rs10995190, G/A HCI  PA 0.86 16% 0.83 20% 
 
 
Table 2. Table of empirical Odds Ratio (OR). A crude PRS was calculated for each 
sample, and was then adjusted based on the average of the controls PRSs. Samples 

















The distribution of subjects among our seven groups showed a bell curve 
centered on the reference group which straddles a normalized PRS of 1.0 (Figure 1). We 
found that the groups with a PRS <1.0 had a larger number of controls than cases, and 
conversely, those groups with a PRS >1.0 had a larger number of cases than controls. 
Thus, the OR for each group with an expected PRS <1.0 was found to be <1.0; 
similarly, those groups with a PRS >1.0 were found to have an OR >1.0 (Figure 1).  
Our null hypothesis states that there would be no risk attributable to the 
polygene model, and so under the null hypothesis, on a graph of PRS vs. ORs (Figure 
2), we would expect no association, with each OR being not significantly different than 
1.0 (i.e. clustered around the y=1 line). Under the alternate hypothesis, that there is 
measurable risk attributable to the polygene, our groups should reflect the normalized 
product of the ORs from the original publications, and cluster around the line x=y. In 
fact we found the latter to be true (Figure 2); the slope of the regression line was 0.97 
with a p-value=6.6*10-5, which overwhelmingly rejects the null hypothesis. We 
recognized that the large number of individuals in our central reference group, which by 
definition has an OR of 1.0, may have been acting to anchor our results, so in order to 
further challenge our results, we excluded the individuals in that central group and 
recalculated the slope and p-value. The recalculated slope was 1.04 and the p-value= 
1.4*10-4 which still rejects the null hypothesis (Figure 3).  
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In looking at the possible clinical utility of this study, we next turned our 
attention to the portion of subjects whose normalized PRS reached the medically 
actionable threshold of equivalence to 20% increased risk (OR>2.0). We found that 
within our sample, 1.2% of controls and 3.6% of cases fell into that group. This 
percentage is similar to the number of individuals found to be at a medically actionable 
level of risk from single intermediate risk gene variants in recent studies by our and 
































Figure 1. Graph of the number of Caucasian of European descent (CEU) cases and 
controls by normalized polygene risk score (PRS). The curve for controls is skewed 
toward ORs less than 1.0; the curve for cases is skewed toward ORs greater than 1.0. 






































Figure 2. Graph of the expected vs. observed OR values by predicted odds ratio group. 
Red crosses are the empirical OR as presented in Table 2 and Figure 1. Each circle 
represents one of the OR groups with the bottom left circle representing OR<0.5 and 
the top right circle representing OR>2.0. The area of each circle is proportional to the 
number of samples in each group. The p-value of 6.6*10-5 strongly rejects the null 








Regression equation =0.97*(predicted OR) +0.0017 
































Figure 3. Graph of the expected vs. observed OR values by group when the central 
group is omitted from calculations. In order to determine whether the large central 
group was anchoring the observed regression, we recalculated the regression and p-
value without the central group. The p-value of 1.4*10-4 still overwhelmingly rejects the 
null hypothesis.  
 
 
Regression equation =1.04*(predicted OR)-0.09  









 For our calculations we used previously published ORs as published by 
COGS and BCAC (Easton, 2007; Michailidou, 2013). Our study included a number of 
non-Caucasian subjects. Because the COGS and BCAC studies focused on Caucasian 
individuals of European descent, the allele frequencies and ORs are not necessarily 
directly applicable to subjects from other populations or ethnicities. Accordingly, we 




When comparing our observed ORs and allele frequencies, we found a few 
notable anomalies when compared with the most recent COGS publication (Michailidou, 
2013). In the case of SNP (rs11249433) 1p11.2, the published allele frequency is 40%, 
but in our sample, we observed the allele frequency to be 53%. In the case of SNP 
(rs2046210) ESR1 and SNP (rs704010) ZMIZ1, the published ORs were each just over 
1.0, while we found their ORs to be slightly under 1.0. In the exact opposite case, SNP 
(rs1045485) Casp8 has a published OR of just under 1.0, while we observed the OR to 
be just over 1.0. In all cases, the discrepancies are likely due to our much smaller 
sample size when compared to the published COGS study. Additionally, because all of 
these ORs are very near to 1.0, they had a negligible effect on our composite PRS. 
15 
 
Common Disease/Common Variant vs. Common Disease/Rare Variant 
 The dichotomous models, Common Disease/ Common Variant (CD/CV) and 
Common Disease/Rare Variant (CD/RV), are often presented in a way that implies that 
one model or the other must be true, and that there is little room for an intermediate 
result or for the two models to work in concert. In fact, the data from this SNP 
genotyping study combined with case-control mutation screening of intermediate risk 
genes in these same subjects (Tavtigian, 2009; LeCalvez-Kelm 2011, Park 2012; 
unpublished Tavtigian lab work) seem to suggest that the CD/CV vs. CD/RV contrast is a 
false dichotomy. In fact, it seems that both models contribute to breast cancer 
susceptibility in the general population. Some individuals have notably elevated risk due 
to the common SNP polygene alone; others are likely to have elevated risk due to a 
single rare variant in an intermediate-risk or high-risk gene. Either way, obtaining a 
more complete estimate of an individual’s genetically determined risk will require 
combining data from their common SNP genotypes with intermediate-risk and high-risk 
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